Neumora Therapeutics (NASDAQ:NMRA) Downgraded to “Strong Sell” Rating by Wall Street Zen

Wall Street Zen cut shares of Neumora Therapeutics (NASDAQ:NMRA) from a sell rating to a strong sell rating in a report published on Saturday.

NMRA has been the topic of several other reports. Royal Bank Of Canada dropped their price target on Neumora Therapeutics from $7.00 to $5.00 and set an “outperform” rating on the stock in a research report on Monday, July 13th. HC Wainwright dropped their target price on shares of Neumora Therapeutics from $18.00 to $7.00 and set a “buy” rating on the stock in a report on Tuesday, June 16th. Guggenheim restated a “buy” rating and issued a $14.00 price target on shares of Neumora Therapeutics in a research report on Tuesday, March 31st. Weiss Ratings restated a “sell (d-)” rating on shares of Neumora Therapeutics in a research note on Friday, July 17th. Finally, Mizuho lowered their target price on Neumora Therapeutics from $6.00 to $4.00 and set an “outperform” rating for the company in a report on Thursday, June 18th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, Neumora Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $6.57.

Neumora Therapeutics Stock Performance

Neumora Therapeutics stock opened at $1.49 on Friday. The stock’s 50-day moving average is $1.65 and its 200-day moving average is $2.16. The company has a market cap of $276.07 million, a price-to-earnings ratio of -1.12 and a beta of 2.74. The company has a debt-to-equity ratio of 0.75, a current ratio of 5.09 and a quick ratio of 5.09. Neumora Therapeutics has a 12 month low of $0.83 and a 12 month high of $3.65.

Neumora Therapeutics (NASDAQ:NMRA) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.02. Equities analysts anticipate that Neumora Therapeutics will post -0.93 earnings per share for the current year.

Institutional Trading of Neumora Therapeutics

Several large investors have recently added to or reduced their stakes in the business. Siren L.L.C. boosted its holdings in Neumora Therapeutics by 35.1% during the first quarter. Siren L.L.C. now owns 8,497,822 shares of the company’s stock valued at $16,571,000 after acquiring an additional 2,209,039 shares during the period. GSA Capital Partners LLP grew its position in Neumora Therapeutics by 392.6% during the fourth quarter. GSA Capital Partners LLP now owns 534,044 shares of the company’s stock worth $956,000 after buying an additional 425,633 shares in the last quarter. Meridian Wealth Management LLC grew its position in Neumora Therapeutics by 45.5% during the fourth quarter. Meridian Wealth Management LLC now owns 86,400 shares of the company’s stock worth $155,000 after buying an additional 27,000 shares in the last quarter. Susquehanna Portfolio Strategies LLC increased its stake in Neumora Therapeutics by 74.8% during the fourth quarter. Susquehanna Portfolio Strategies LLC now owns 72,106 shares of the company’s stock valued at $129,000 after acquiring an additional 30,866 shares during the period. Finally, Invesco Ltd. increased its stake in Neumora Therapeutics by 151.1% during the first quarter. Invesco Ltd. now owns 123,655 shares of the company’s stock valued at $124,000 after acquiring an additional 74,406 shares during the period. 47.65% of the stock is owned by institutional investors.

Neumora Therapeutics Company Profile

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.